Menveo

May 7, 2010 VIA FACSIMILE AND CERTIFIED MAIL RETURN RECEIPT REQUESTED John P. Barry, Ph.D. Drug Regulatory Affairs Novartis Vaccines and Diagnostics, Inc. 350 Massachusetts Avenue Cambridge, MA  02139 Re:       Menveo [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide                Diphtheria CRM197 Conjugate Vaccine] BLA STN# 125300 Dear Dr.  Barry: The Office of Compliance and Biologics…

Flebogamma DIF 5% & 10%

<!– –> <!– Page Last Updated: 01/21/2016 –> Page Last Updated: 01/21/2016 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

October 27, 2015 Approval Letter

%PDF-1.7% 250 0 objendobj 266 0 obj/Filter/FlateDecode/ID[]/Index[250 31]/Info 249 0 R/Length 82/Prev 71957/Root 251 0 R/Size 281/Type/XRef/W[1 2 1]stream hbbd“b`z$ׂX{$`”N6X, b? “$Aڔwe$.23012tY~0

Order to Cease Manufacturing and to Retain HCT/Ps

August 18, 2006 HAND DELIVERED Philip GuyettOwnerDonor Referral Services4724 Hargrove RoadRaleigh, NC 27616 Dear Mr. Guyett: The Food and Drug Administration (FDA or the agency) conducted an inspection of your establishment, Donor Referral Services (DRS or Establishment), at 4724 Hargrove Road, Raleigh, North Carolina 27616, which manufactures human cells, tissues, and cellular and tissue-based products…